Vaccines & BioPharma
FDA to Hold Expert Committee Meeting on Moderna Flu Vaccine
By Intent.Health Team • May 21, 2026
What’s happening
The FDA scheduled an expert advisory committee meeting to review Moderna's experimental flu vaccine.
The vaccine uses mRNA technology, the same platform that helped make Moderna's COVID vaccine successful.
What’s changing / Business impact
The upcoming evaluation marks major operational updates:
- Serves as an important step toward possible regulatory approval
- Accelerates the expansion of mRNA technology into seasonal flu prevention
- Drives increased market competition in the commercial flu vaccine sector
Why this matters
Drug companies are aggressively trying to scale and deploy mRNA technology platforms well beyond COVID applications.
This pipeline pivot shows mRNA may become a foundational vaccine platform for multiple diseases, even as regulators continue closely evaluating long-term clinical effectiveness.